The Prevalence of Occult Malignancy in Women Undergoing Hysterectomy or Myomectomy for Benign Indications and the Impact of Morcellation on Survival Outcomes: A Meta-Analysis.
Dan Jiang, Hongxuan Liu, Kui Huang, Yan Chen, Qiao Liu, Chuqiang Shu, Qi Tian
{"title":"The Prevalence of Occult Malignancy in Women Undergoing Hysterectomy or Myomectomy for Benign Indications and the Impact of Morcellation on Survival Outcomes: A Meta-Analysis.","authors":"Dan Jiang, Hongxuan Liu, Kui Huang, Yan Chen, Qiao Liu, Chuqiang Shu, Qi Tian","doi":"10.1159/000542894","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Uterine fibroids (UFs), also known as leiomyomas, are the most common benign gynecological tumors. Currently, morcellation is discouraged due to the risk of disseminating undetected malignancies. This study aimed to update the prevalence data on occult malignancies in surgeries for suspected benign uterine lesions and analyze the impact of treatment strategies on the survival outcomes in patients with occult malignancy.</p><p><strong>Methods: </strong>Five English-language literature databases were systematically searched up to July 25, 2024, for studies reporting the incidence of occult malignancies in patients with suspected UFs and their survival outcomes. The study was preregistered on PROSPERO (CRD42024580233).</p><p><strong>Results: </strong>A total of 34 studies were included in the analysis. The pooled incidence of occult malignancies, calculated using a random-effects model, was 2.88 (2.10-3.94) per 1,000 individuals. Significant regional variations were observed in the subgroup comparisons (p < 0.01). Morcellation did not significantly affect progression-free survival (PFS) (hazard ratio [HR]: 1.26, 95% confidence interval [CI]: 0.86-1.84, p = 0.240) or overall survival (OS) (HR: 1.13, 95% CI: 0.70-1.82, p = 0.614). Pooled analysis of HR revealed that chemotherapy significantly improved PFS (HR: 0.49; 95% CI: 0.32-0.77; p = 0.002) and OS (HR: 0.49; 95% CI: 0.28-0.87; p = 0.015).</p><p><strong>Conclusions: </strong>The incidence of occult malignancies in women undergoing hysterectomy or myomectomy for benign conditions is approximately 2.88 per 1,000 individuals. Morcellation does not impact survival outcomes, whereas adjuvant chemotherapy provides a survival benefit. Further well-designed clinical trials are required to validate these findings.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-14"},"PeriodicalIF":2.0000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic and Obstetric Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542894","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Uterine fibroids (UFs), also known as leiomyomas, are the most common benign gynecological tumors. Currently, morcellation is discouraged due to the risk of disseminating undetected malignancies. This study aimed to update the prevalence data on occult malignancies in surgeries for suspected benign uterine lesions and analyze the impact of treatment strategies on the survival outcomes in patients with occult malignancy.
Methods: Five English-language literature databases were systematically searched up to July 25, 2024, for studies reporting the incidence of occult malignancies in patients with suspected UFs and their survival outcomes. The study was preregistered on PROSPERO (CRD42024580233).
Results: A total of 34 studies were included in the analysis. The pooled incidence of occult malignancies, calculated using a random-effects model, was 2.88 (2.10-3.94) per 1,000 individuals. Significant regional variations were observed in the subgroup comparisons (p < 0.01). Morcellation did not significantly affect progression-free survival (PFS) (hazard ratio [HR]: 1.26, 95% confidence interval [CI]: 0.86-1.84, p = 0.240) or overall survival (OS) (HR: 1.13, 95% CI: 0.70-1.82, p = 0.614). Pooled analysis of HR revealed that chemotherapy significantly improved PFS (HR: 0.49; 95% CI: 0.32-0.77; p = 0.002) and OS (HR: 0.49; 95% CI: 0.28-0.87; p = 0.015).
Conclusions: The incidence of occult malignancies in women undergoing hysterectomy or myomectomy for benign conditions is approximately 2.88 per 1,000 individuals. Morcellation does not impact survival outcomes, whereas adjuvant chemotherapy provides a survival benefit. Further well-designed clinical trials are required to validate these findings.
期刊介绍：
This journal covers the most active and promising areas of current research in gynecology and obstetrics. Invited, well-referenced reviews by noted experts keep readers in touch with the general framework and direction of international study. Original papers report selected experimental and clinical investigations in all fields related to gynecology, obstetrics and reproduction. Short communications are published to allow immediate discussion of new data. The international and interdisciplinary character of this periodical provides an avenue to less accessible sources and to worldwide research for investigators and practitioners.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
